BXCL701

A Phase 1 Study of BXCL701 in Relapsed/Refractory Acute Myeloid Leukemia or Relapsed/Refractory Myelodysplastic Syndrome With Excess Blasts - 2

More Information

Trial Status
Accepting patients
Trial Phase
Phase 1
Enrollment
24 patients (estimated)
Sponsors
Dana-Farber Cancer Institute
Tags
Dipeptidyl Peptidase 4 (DPP-4) Inhibitor
Trial Type
Treatment
Last Update
1 month ago
SparkCures ID
1488
NCT Identifier
NCT05703542

Real People. Real Support.

Need help connecting with this clinical trial? We're here to help!

Print a patient-friendly report to share with your patient.

We can help answer any questions and connect you (or your patient) with the study team.

Schedule a time that is convenient and we’ll call you to see how we can help you and your patient.